Research graph
References from Envonalkib Versus Crizotinib in Treatment‐Naive <i>ALK</i> ‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Third‐Generation EGFR and ALK Inhibitors: Mechanisms of Resistance and Management
10.1038/s41571-022-00639-9 · 2022 · External reference
Clinical Characteristics and Sequence Complexity of Anaplastic Lymphoma Kinase Gene Fusions in Chinese Lung Cancer Patients
10.1016/j.lungcan.2017.11.001 · 2017 · External reference
First‐Line Crizotinib Versus Chemotherapy in ALK‐Positive Lung Cancer
10.1056/nejmoa1408440 · 2014 · External reference
Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib Versus Chemotherapy in East Asian Patients With ALK‐Positive Advanced Non‐Small Cell Lung Cancer
10.1016/j.jtho.2018.06.012 · 2018 · External reference
Alectinib Versus Chemotherapy in Crizotinib‐Pretreated Anaplastic Lymphoma Kinase (ALK)‐Positive Non‐Small‐Cell Lung Cancer: Results From the Phase III ALUR Study
10.1093/annonc/mdy121 · 2018 · External reference
Multicenter Phase II Study of Whole‐Body and Intracranial Activity With Ceritinib in Patients With ALK‐Rearranged Non‐Small‐Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND‐2
10.1200/jco.2015.65.5936 · 2016 · External reference
Brigatinib in Patients With Crizotinib‐Refractory Anaplastic Lymphoma Kinase–Positive Non–Small‐Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
10.1200/jco.2016.71.5904 · 2017 · External reference
Efficacy, Safety, and Biomarker Analysis of Ensartinib in Crizotinib‐Resistant, ALK‐Positive Non‐Small‐Cell Lung Cancer: A Multicentre, Phase 2 Trial
10.1016/s2213-2600(19)30252-8 · 2020 · External reference
Lorlatinib in Patients With ALK‐Positive Non‐Small‐Cell Lung Cancer: Results From a Global Phase 2 Study
10.1016/s1470-2045(18)30649-1 · 2018 · External reference
Pharmacologic Characterization of CT‐711, a Novel Dual Inhibitor of ALK and c‐Met
2018 · External reference
Envonalkib Versus Crizotinib for Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: A Randomized, Multicenter, Open‐Label, Phase III Trial
10.1038/s41392-023-01538-w · 2023 · External reference
Prognosis of ALK‐Rearranged Non‐Small‐Cell Lung Cancer Patients Carrying TP53 Mutations
10.1016/j.tranon.2022.101471 · 2022 · External reference
Impact of TP53 Mutation Status on Systemic Treatment Outcome in ALK‐Rearranged Non‐Small‐Cell Lung Cancer
10.1093/annonc/mdy333 · 2018 · External reference
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK‐Rearranged NSCLC
10.1016/j.jtho.2023.08.007 · 2024 · External reference
Correlation of Baseline Molecular and Clinical Variables With ALK Inhibitor Efficacy in ALTA‐1L
10.1200/jco.2020.38.15_suppl.9517 · 2020 · External reference
Decoding the Evolutionary Response to Ensartinib in Patients With ALK‐Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
10.1016/j.jtho.2021.01.1615 · 2021 · External reference
Co‐Occurring Genetic Alterations and Primary EGFR T790M Mutations Detected by NGS in Pre‐TKI‐Treated NSCLCs
10.1007/s00432-019-03065-0 · 2019 · External reference
Impact of Tumor‐Intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK‐Positive NSCLC
10.1158/2767-9764.crc-24-0065 · 2024 · External reference
TP53 or CDKN2A/B Covariation in ALK/RET/ROS1‐Rearranged NSCLC Is Associated With a High TMB, Tumor Immunosuppressive Microenvironment and Poor Prognosis
10.1007/s00432-023-04924-7 · 2023 · External reference
Overcoming Therapy Resistance in EGFR‐Mutant Lung Cancer
10.1038/s43018-021-00195-8 · 2021 · External reference
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
10.1158/2159-8290.cd-22-1420 · 2023 · External reference
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient‐Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
10.1016/j.jtho.2023.05.007 · 2023 · External reference
Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3‐RET Fusion in EGFR‐Mutated Non‐Small‐Cell Lung Cancer
10.1200/po.22.00040 · 2022 · External reference
Understanding the Complexity of p53 in a New Era of Tumor Suppression
10.1016/j.ccell.2024.04.009 · 2024 · External reference
Targeting ALK: Precision Medicine Takes on Drug Resistance
10.1158/2159-8290.cd-16-1123 · 2017 · External reference
A Nanotherapeutic Strategy to Target Drug‐Tolerant Cells and Overcome EGFR Tyrosine Kinase Inhibitor Resistance in Lung Cancer
10.1002/cac2.12401 · 2023 · External reference
Molecular Mechanisms of Resistance to First‐ and Second‐Generation ALK Inhibitors in ALK‐Rearranged Lung Cancer
10.1158/2159-8290.cd-16-0596 · 2016 · External reference
Precision Medicine in Non‐Small Cell Lung Cancer: Current Applications and Future Directions
10.1016/j.semcancer.2020.07.009 · 2022 · External reference
Targeting ALK Rearrangements in NSCLC: Current State of the Art
10.3389/fonc.2022.863461 · 2022 · External reference
Updated Overall Survival and Final Progression‐Free Survival Data for Patients With Treatment‐Naive Advanced ALK‐Positive Non‐Small‐Cell Lung Cancer in the ALEX Study
10.1016/j.annonc.2020.04.478 · 2020 · External reference
Brigatinib Versus Crizotinib in ALK Inhibitor‐Naive Advanced ALK‐Positive NSCLC: Final Results of Phase 3 ALTA‐1L Trial
10.1016/j.jtho.2021.07.035 · 2021 · External reference
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non‐Small Cell Lung Cancer
10.1001/jamaoncol.2021.3523 · 2021 · External reference
Lorlatinib Versus Crizotinib in Patients With Advanced ALK‐Positive Non‐Small Cell Lung Cancer: 5‐Year Outcomes From the Phase III CROWN Study
10.1200/jco.24.00581 · 2024 · External reference
629MO ALESIA 7‐Year Update: Alectinib vs Crizotinib in Asian Patients (pts) With Treatment‐Naïve Advanced ALK+ Non‐Small Cell Lung Cancer (NSCLC)
10.1016/j.annonc.2024.10.662 · 2024 · External reference
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
10.1016/j.jtho.2019.08.003 · 2019 · External reference
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK‐Positive Lung Cancer
10.1158/1078-0432.ccr-19-3906 · 2020 · External reference
Mechanisms of Acquired Crizotinib Resistance in ALK‐Rearranged Lung Cancers
10.1126/scitranslmed.3003316 · 2012 · External reference
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4‐ALK‐Positive Non‐Small Cell Lung Cancer
10.1158/1078-0432.ccr-12-0392 · 2012 · External reference
Brigatinib in Japanese Patients With ALK‐Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J‐ALTA Trial
10.1016/j.jtho.2020.11.004 · 2021 · External reference
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase‐Positive Non‐Small‐Cell Lung Cancer
10.1200/jco.18.02236 · 2019 · External reference
